- Home
- ORIC vs GHRS Comparison
ORIC vs GHRS Comparison
Compare ORIC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | GHRS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.3M | 947.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORIC | GHRS |
|---|---|---|
| Price | $7.60 | $21.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $19.73 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.5M | 211.2K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $11.32 |
| 52 Week High | $14.93 | $25.94 |
Technical Indicators
Market Signals| Indicator | ORIC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 46.78 |
| Support Level | N/A | $12.79 |
| Resistance Level | $13.89 | $22.88 |
| Average True Range (ATR) | 0.51 | 1.71 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 18.46 | 4.41 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.